American Herbal Products Association (AHPA) > About Us > Committees > Government Relations Committee

Government Relations Committee

Chair: Staci Eisner (Cortex Scientific)
Staff Contact: Michael McGuffin

Committee Purpose:

  • To monitor legislative and regulatory issues and agencies for the purpose of developing industry positions that conform to AHPA's mission.

AHPA Members, if you would like to join this committee, please email the staff contact.

Committee Resources

Committee Meeting Minutes

August 4, 2021 Meeting Minutes

Meeting of the Government Relations Committee

June 3, 2021 Meeting Minutes

Meeting of the Government Relations Committee

April 27, 2021 Meeting Minutes

Meeting of the Government Relations Committee

March 3, 2021 Meeting Minutes

Meeting of the Government Relations Committee

January 7, 2021 Meeting Minutes

Meeting of the Government Relations Committee


Committee-Related News

AHPA letter to new US Trade Representative requests tariff relief

June 2021 - Letter also cites the organization’s extensive previous comments to the USTR on this matter

The American Herbal Products Association (AHPA) delivered a letter to US Trade Representative Katherine Tai this month requesting the removal of punitive tariffs from a range of products relevant to the herbal products industry.

AHPA releases 2021 update to free Primer on Convention on International Trade in Endangered Species (CITES)

May 2021 Revision

AHPA has updated its “Primer on Importing and Exporting CITES-Listed Species,” a free resource that provides the herbal industry with the latest information on the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES).

California bill restricting minor access to supplements deferred to 2022

May 21, 2021 - Bill held by Appropriations Committee until assembly reconvenes in January

A recent California Assembly Bill 1341 (AB 1341) that would place heavy restrictions on a broad range of dietary supplements has been held up in the state Appropriations Committee, seriously delaying its passage.

Bipartisan Legislation Introduced in U.S. Senate Would Create Regulatory Pathways for Use of Hemp-Derived CBD in Dietary Supplements and Conventional Food

May 2021 - Bill would remove restrictions for use in foods and dietary supplements

Silver Spring, MD, May 19, 2021 – Today, Senators Ron Wyden and Jeff Merkley (D-OR) and Senator Rand Paul (R-KY) introduced bipartisan legislation that would protect public health by providing legal clarity in the hemp and hemp-derived cannabidiol (CBD) product marketplace.

AHPA requests CITES exemption for cultivated American ginseng

Comments submitted to U.S. FWS in preparation for CoP19

In comments submitted to the U.S. Fish and Wildlife Service (FWS), the American Herbal Products Association (AHPA) requested that FWS recommend the removal of artificial-shade grown American ginseng (Panax quinquefolius) from that species’ listing on Appendix II of the Convention on International Trade in Endangered Species (CITES).

AHPA submits comments to FDA proposed rule on traceability for “certain foods”

March 1, 2021: Association requests appropriate scope for “herbs” listing, consideration of a supplemental proposed rule

In comments submitted to the U.S. Food and Drug Administration (FDA) on Monday, AHPA has requested significant revisions and clarifications to a proposed rule that would establish new, additional traceability recordkeeping requirements for categories of foods on a newly published “Food Traceability List.” (FTL)

AHPA requests adequate federal funding for USPS

July 1, 2020: AHPA members depend on the Postal Service to transport herbal products

AHPA President Michael McGuffin sent a letter to Congressional leaders in the U.S. House and Senate to request adequate federal funding be included in a fourth COVID-19 relief package to ensure the financial viability and continued operations of the United States Postal Service (USPS).

Oregon adopts temporary rule prohibiting unsubstantiated claims that goods prevent, treat, diagnose, or mitigate COVID-19 related conditions

April 17, 2020: AHPA has been working with other trade organizations to seek withdrawal of a much-broader proposed rule that the OR DOJ published for comment late last year and in amended form in March 2020.

The Oregon Department of Justice (OR DOJ) has temporarily adopted a rule declaring it “unfair and deceptive” (and thus unlawful) to represent that any product “will prevent, treat, diagnose, mitigate, or cure coronavirus, COVID-19 or a related condition, without first having competent and reliable scientific evidence upon which to base a reasonable belief in the truth of the representation.” The temporary rule is effective for six months, until October 14, 2020.
Adverse event reporting tells the story of dietary supplement safety

Adverse event reporting tells the story of dietary supplement safety

March 3, 2020: FDA AER data often lacks fields that may prevent misinterpretation, including FDA’s assessment of causation

Washington, D.C. — At the initial Congressional Dietary Supplement Caucus briefing of 2020, held last week, Dr. Richard Kingston, president, regulatory and scientific affairs and co-founder of SafetyCall International, educated congressional staffers on the types of evidence used to monitor dietary supplement safety, including adverse event reports, emergency room visits and poison control center data. Dr. Kingston is an expert on clinical toxicology and pharmacology, poison control, product post-market surveillance, and drug and dietary supplement safety.